Zydus receives final approval from US regulator for Azithromycin tablets
Z
ydus Lifesciences on Monday said it has received the final approval from the United States Food and Drug Administration (USFDA) to manufacture and market Azithromycin Tablets USP, 500 mg.
Azithromycin is prescribed to treat certain bacterial infections such as bronchitis, pneumonia, sexually transmitted diseases (STD), and infections of the ears, lungs, sinuses, skin, throat, and reproductive organs.
The drug will be manufactured at the group's formulation manufacturing facility in Moraiya, Ahmedabad, it informed stock exchanges.
Azithromycin Tablets USP, 500 mg has about annual sales of USD 20 million in the US.
✔️ Zydus receives final approval from US regulator for Azithromycin tablets
💕 Found this article helpful? Spread the word and support us!